Sanofi (NASDAQ:SNY) Shares Sold by Greenleaf Trust

Greenleaf Trust lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 30.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,592 shares of the company’s stock after selling 4,222 shares during the quarter. Greenleaf Trust’s holdings in Sanofi were worth $463,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SNY. Avantra Family Wealth Inc. acquired a new stake in shares of Sanofi during the fourth quarter worth approximately $673,000. DAVENPORT & Co LLC increased its position in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Sanofi by 13.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,845 shares of the company’s stock worth $3,079,000 after purchasing an additional 7,615 shares during the last quarter. Keudell Morrison Wealth Management lifted its position in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after purchasing an additional 217 shares during the last quarter. Finally, Cibc World Market Inc. lifted its position in shares of Sanofi by 3.4% during the fourth quarter. Cibc World Market Inc. now owns 315,888 shares of the company’s stock worth $15,235,000 after purchasing an additional 10,328 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SNY has been the topic of several research reports. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Stock Up 0.3 %

Shares of Sanofi stock opened at $53.50 on Wednesday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a market capitalization of $135.77 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 1.26 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. The business’s 50 day simple moving average is $49.44 and its 200-day simple moving average is $52.34.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities research analysts forecast that Sanofi will post 4.34 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.